Shares of Year On Friday on Friday by 14% and rose with a brand new 52-week high, which defeated the profits with the expectations of Wall Street.

In an interview about CNBCs “Squawk Box”, CEO Anthony Wood said that greater than half of US broadband households now watch with Roku.

According to Wood, the corporate added greater than 4 million recent streaming households within the last quarter and on the suitable track next yr to succeed in 100 million streaming households.

The company's growth was partly driven by the Roku user experience, including the promotion of content on the beginning screen, said Wood by Julia Boorstin from CNBC.

“We are the streaming operating system No. 1 in the country and in most America with a big lead,” he said.

Just like the corporate carried out for the fourth quarter Compared to the expectations of Wall Street, LSEG relies on a survey of LSEG analysts:

• Loss per share: 24 cents expected in comparison with a lack of 40 cents
• Revenue: 1.2 billion US dollars are expected in comparison with 1.14 billion US dollars

The company increased sales by 22% to 1.2 billion US dollars. It reported a net loss for the period of USD 35.5 million or 24 cents per share, an improvement in comparison with a net lack of $ 78.3 million or 55 cents per share in the identical quarter within the previous yr.

Roku reported 89.8 million households by the top of 2024, which was 12%in comparison with the previous yr. From the subsequent quarter, the corporate now not expects to report this metric if it optimizes the winning reports in an effort to concentrate on sales and profitability figures.

In the fourth quarter, Roku also recorded a rise in streaming working hours in the middle of the yr by 18%, whereby the main focus was on further increasing the demand for promoting by “deeper platform integrations of third-party bidders”, the corporate said in its earnings publication.

“Advertising is a large part of our business, and therefore a big focus for us in our strategy is to further increase demand by working with partners of third -party providers,” said Wood.

The company predicts net sales of $ 1 billion and a gross profit of $ 450 million for the primary quarter of 2025.

South Korea SK Hynixone among the world's largest memory chip makers, reported record quarterly profit on Thursday, driven by strong demand for its high-bandwidth memory (HBM), which is utilized in generative AI.

Here are SK Hynix's third-quarter results in comparison with LSEG SmartEstimate, which relies on analyst forecasts which might be consistently more accurate:

• Revenue: 17.57 trillion won (US$12.7 billion) versus 18.11 trillion won
• Operating profit: 7.03 trillion won (US$5.08 billion) versus 6.8 trillion won

Operating profit hit its highest level within the July-September quarter, recovering from a lack of 1.8 trillion won within the 12 months same period last 12 months.

Quarterly revenue rose about 94% year-on-year to 9.1 trillion won.

The South Korean chip giant is a key supplier to Nvidia and is benefiting from the boom in servers with artificial intelligence.

SK Hynix said in his Results publication On Thursday, the corporate said demand for AI storage, particularly from data center customers, remained strong within the third quarter, allowing the corporate to extend sales of premium products comparable to HBM.

HBM is a sort of dynamic random access memory, often known as DRAM, by which chips are stacked vertically to save lots of space and reduce power consumption. DRAM is often utilized in laptops, workstations and PCs. SK Hynix, Micron Technology and Samsung Electronics are the three largest manufacturers of HBM chips.

Sales of HBM products also increased by greater than 70% in comparison with the previous quarter and greater than thrice in comparison with the identical period last 12 months, with the corporate expecting further growth.

“While the storage requirements for AI servers like HBM and [high-density enterprise SSD] “Grown significantly this year, the company expects this trend to continue next year,” the corporate said in an announcement Press release. Enterprise SSD is a knowledge storage device for servers.

Generative AI continues to advance and major technology firms are investing in developing the technology that supports demand, the corporate said.

SK Hynix also predicted that memory demand within the PC and mobile consumer products markets, which has been slower to get well from a downturn, shall be on a gentle growth path next 12 months amid the emergence of AI-optimized devices.

“As the application of AI technology expands, the application of storage is also expected to increase, which will lead to even more stable storage market growth in the future,” Kim Woohyun, vp and chief financial officer at SK Hynix, said in a conference call to the outcomes.

In 2023, the memory market experienced a pointy downturn brought on by oversupply, weak end-market demand, and geopolitical tensions Fitch Ratings.

The company announced this last month It has began mass production its latest version of HBM chips and is aiming for delivery by the top of the 12 months.

When markets opened in South Korea on Thursday, shares of SK Hynix initially fell 0.4% but then recovered to rise 1.3%.

Bristol Myers Squibb on Thursday reported first-quarter revenue that beat expectations as sales of its popular blood cancer drug Revlimid and blockbuster blood thinner Eliquis got here in higher than expected.

However, the pharmaceutical company posted a quarterly loss resulting from one-time charges related to its recently concluded deals. The company also said it might cut costs by $1.5 billion by 2025 and reinvest the cash into drug development.

Bristol Myers will lay off 2,200 employees this yr, end some drug programs, eliminate open positions, consolidate its locations and reduce management levels, amongst other cost savings. The company said it might prioritize investments in its key drug brands, optimize operations across the corporate and focus its resources on research and development programs that would deliver the very best returns to the corporate and the best health advantages to patients.

Two-thirds of the savings are tied to drug research and development, Bristol Myers executives said during a conference call Thursday. The company has discontinued about 12 drug programs to this point and can consider discontinuing additional programs all year long, Dr. Samit Hirawat, Chief Medical Officer of Bristol Myers.

Bristol Myers CEO Chris Boerner added that the vast majority of savings will come from existing internal operations slightly than newly acquired corporations.

“We are taking important actions to effectively navigate the decade,” Boerner said throughout the call. “Our management team has been focused on ensuring the discipline needed to achieve both this year and position ourselves for the longer term.”

For the primary quarter, Bristol Myers said the fees weighing on the corporate were primarily resulting from this Acquisition valued at $14 billion the neuroscientific drug manufacturer Karuna Therapeutics and the Cooperation agreement with SystImmune, a subsidiary of a Chinese biotech startup, to jointly develop and commercialize its experimental cancer treatment.

These deals come as Bristol Myers faces pressure to bring latest drugs to market and offset potential lost sales of its top-selling treatments. The company's popular blood cancer drug Revlimid – and eventually Eliquis and cancer immunotherapy Opdivo – face competition from cheaper copycats.

Shares of Bristol Myers fell greater than 7% on Tuesday.

Here's what Bristol Myers reported for the primary quarter in comparison with Wall Street's expectations, based on an LSEG analyst survey:

• Loss per share: $4.40 adjusted versus an expected lack of $4.44
• Revenue: $11.87 billion versus expected $11.46 billion

Bristol Myers, considered one of the world's largest pharmaceutical corporations, reported a first-quarter net lack of $11.9 billion, or $5.89 per share. By comparison, net income for a similar period last yr was $2.3 billion, or $1.07 per share.

Excluding certain items, adjusted loss per share was $4.40 for the period.

The loss reflects a one-time charge of $6.30 per share related to recently accomplished deals, Bristol Myers said in a news release.

Bristol Myers reported first-quarter revenue of $11.87 billion, up 5% from the identical period last yr.

The company reiterated its full-year revenue forecast for a low single-digit increase. But Bristol Myers cut its 2024 adjusted earnings forecast to 40 cents to 70 cents per share to reflect the impact of recent deals.

This compares to previous guidance of $7.10 to $7.40 per share, which excluded costs related to the acquisitions of Karuna Therapeutics and radiopharmaceutical company RayzeBio, in addition to divestitures and other items.

Bristol Myers said first-quarter sales growth was primarily resulting from higher sales of Eliquis and a few of its newer drugs.

Eliquis reported revenue of $3.72 billion within the quarter, up 9% from the identical period last yr. Analysts had expected Eliquis to generate $3.59 billion in sales, in accordance with estimates from FactSet.

Eliquis, with whom Bristol Myers shares Pfizer, is among the many first 10 drugs for which pricing negotiations are ongoing with the federal Medicare program. The blood thinner is predicted to lose its market exclusivity by 2028.

The impact of those negotiations on Eliquis stays unclear, Bristol Myers executives said throughout the call. The final negotiated price for the drug can be published later this yr and can take effect in 2026. The company then expects a decline in sales and profits.

Meanwhile, Revlimid posted revenue of $1.67 billion, down 5% from the identical period last yr.

But that beat analysts' sales expectations of $1.22 billion for the drug, in accordance with FactSet estimates.

Anemia drug Reblozyl and advanced melanoma treatment Opdualag also posted sales growth in the primary quarter.

Reblozyl reported revenue of $354 million, up 72% from the identical period last yr. Analysts had expected revenue of $330.8 million, in accordance with FactSet.

Opdualag reported first-quarter revenue of $206 million, up 76% from the identical period last yr. Analysts had expected revenue of $206.5 million, in accordance with FactSet estimates.

The performance of other latest drugs fell in need of Wall Street expectations.

Abecma, a cell therapy for a rare blood cancer called multiple myeloma, had sales of $82 million within the quarter. According to FactSet, analysts had expected sales of $112.6 million.

The U.S. Food and Drug Administration expanded its approval for this drug earlier this month, allowing patients with multiple myeloma to make use of it as an earlier line of treatment.

An older drug, Opdivo, posted sales of $2.07 billion within the quarter, down 6% from the primary quarter of 2023. Analysts had expected the drug to post sales of $2.3 billion for the period, in accordance with FactSet estimates.

Johnson & Johnson on Tuesday reported First-quarter adjusted earnings beat Wall Street expectations, as did sales Medical equipment business increased.

Meanwhile, the corporate's total revenue through the period was largely in step with estimates.

J&J's medtech division offers surgical, orthopedic and vision devices. The company is benefiting from a recovery in demand for non-urgent surgeries amongst older adults, who’ve postponed these procedures through the Covid pandemic. This increased demand has been observed by health insurers Humana, UnitedHealth Group and Elevance Health.

J&J CFO Joseph Wolk told CNBC's “Squawk Box” on Tuesday that customers could also be pulling back in other areas but “don't want to compromise when it comes to their health, their mobility and their ability to “to live a fulfilled life.” He added that the company has seen increased caseloads due to Covid and “has not seen any regression from this”.

Here's what J&J reported for First quarter compared to Wall Street expectations based on an analyst survey by LSEG:

• Earnings per share: $2.71 adjusted vs. $2.64 expected
• Revenue: $21.38 billion versus expected $21.4 billion

J&J's financial results are considered benchmarks for the entire healthcare sector.

The company reported total revenue of $21.38 billion for the first three months of 2024, up more than 2% from the same quarter in 2023.

The pharmaceutical giant reported net income of $5.35 billion, or $2.20 per share, for the quarter. That compares with a net loss of $491 million, or 19 cents per share, in the year-ago period. At that time, J&J recorded costs related to its talc baby powder liabilities and the spinoff of its consumer health division Kenvue.

Excluding certain items for the first quarter of 2024, adjusted earnings per share were $2.71.

J&J also cut its full-year guidance. The company now expects sales of $88 billion to $88.4 billion. That compares with a previous forecast of $87.8 billion to $88.6 billion.

J&J expects adjusted earnings of $10.57 to $10.72 per share. This compares to a previous forecast of $10.55 to $10.75 per share.

Separately, J&J said Tuesday that it will increase its quarterly dividend is $1.24 per share, up 4.2% from $1.19 per share. This is the 62nd consecutive year of dividend increases for the company, it said. The dividend is payable on June 4th.

The results come weeks after J&J's whopping $13.1 billion acquisition of the cardiac device maker Shockwave Medical – part of its push into the cardiovascular space. Both companies said the deal will make J&J the market leader in four fast-growing cardiovascular technology categories.

J&J has acquired two other cardiac device companies in the past two years, spending $16.6 billion to buy Abiomed and $400 million to acquire privately held Laminar.

These deals are also aimed at strengthening J&J's medical device business following the company's separation from its consumer health division Kenvue last year.

J&J's medical device business generated first-quarter revenue of $7.82 billion, up more than 4% from a year ago. According to StreetAccount estimates, Wall Street expected sales of $7.87 billion.

J&J said the Abiomed acquisition fueled the year-over-year increase. Growth was also driven by electrophysiology products that assess the heart's electrical system and help doctors understand the cause of cardiac arrhythmias, J&J said.

Wound closure products and devices for orthopedic trauma or severe injuries to the skeletal or muscular system as well as contact lenses contributed to this.

Meanwhile, J&J reported pharmaceutical sales of $13.56 billion, up about 1% year over year. Excluding sales of its unpopular Covid vaccine, sales in the pharmaceutical division rose almost 7%.

It was the fourth quarter excluding U.S. sales of J&J's Covid vaccine, which brought in $25 million in international sales.

According to StreetAccount, analysts expected revenue of $13.5 billion for the business segment. Also known as “Innovative Medicine,” the company focuses on developing drugs for various disease areas.

The company said the growth was driven by sales of Darzalex, a biologic used to treat multiple myeloma, and Erleada, a treatment for prostate cancer. J&J's Carvykti, a cell therapy approved for a type of blood cancer, and other oncology treatments also contributed to the increase.

But sales of the company's blockbuster drug Stelara, used to treat several chronic and potentially disabling diseases such as Crohn's disease, were relatively flat in the first quarter compared to the same period last year.

Stelara had revenue of $2.45 billion in the quarter. Wall Street expected sales of $2.61 billion.

J&J began losing patent protection for Stelara late last year, allowing cheaper biosimilar competitors to enter the market. But the company has signed settlement agreements with Amgen and other drugmakers to delay the launch of some Stelara copycats until 2025.

J&J's first-quarter results come amid investor concern over tens of thousands of lawsuits alleging that the company's talc-based products were contaminated with the carcinogen asbestos and caused ovarian cancer and several deaths.

These products, which include J&J's eponymous baby powder, now fall under Kenvue. However, J&J assumes all talc-related liabilities arising in the United States and Canada.

Notably, a federal judge ruled in March that J&J can challenge scientific evidence linking its talc products to ovarian cancer, potentially disrupting a federal court case consolidating 53,000 lawsuits.

Wolk on Tuesday called that ruling a “very significant development” and said the evidence presented against J&J was “junk science.” However, he noted that it was difficult to provide a timeline for when the company would find a comprehensive resolution to the ongoing litigation.

In January, J&J said it had reached a preliminary agreement solve one Investigation from greater than 40 states in allegations that the corporate misled patients about it Security of its talc-based products. The company pays $700 million to settle the investigation, its chief financial officer Joseph Wolk said said the Wall Street Journal by the point.

Last yr, J&J provided about $400 million to resolve U.S. states' consumer protection claims.

Notably, the settlement doesn’t resolve the lawsuits, a few of that are scheduled to go to trial later this yr.

J&J will hold a conference call with investors on Tuesday at 8:30 a.m. ET.